|
| Having trouble viewing this email? Click here to view in your web browser. |
 |
|
| Delivering innovative, patient-centric formulations |
|
| Dear [insert recipient]: |
|
|
|
| I hope that you found CPhI Japan 2016 to be informative and beneficial. |
|
| With decades of expertise in oral drug formulation, I believe that Adare Pharmaceuticals has something unique to offer your company. Our capabilities allow our partners to differentiate their products early in development or throughout life-cycle management. By applying our proprietary technologies, we can help achieve |
|
| desired target product profiles that may help address the needs of specific patient populations, such as pediatric, geriatric, and dysphagic patients. Additionally, we have a diverse portfolio of products available for out-licensing. By applying our proprietary formulation technologies, we have created new products with proven patient-centric benefits. |
|
Another advantage of working with Adare is our extensive experience with the quality standards and
regulatory requirements of Asian markets. Since 2009, our partnerships have resulted in over
60 product launches in 44 countries, including Japan and other Asian markets. |
|
| I hope that this information is helpful as you consider future partnership opportunities. Please feel free to contact me to discuss how Adare can serve your business needs. |
|
Sincerely,
|
|
Holger Neecke
Director Business Development |
|
 |
|
Adare Pharmaceuticals S.r.l.
Via Martin Luther King, 13, 20060 Pessano con Bornago (MI) Italia
Capitale Sociale € 1.000.000 | CF/P.IVA/Registro imprese di Milano 09008820962
Tel: +39 02 95428371 | Mobile: +39 342 9156501 | Fax: +39 02 95428383
[email protected] | www.AdarePharma.com |
| |
| |
|
| ©2016 Adare Pharmaceuticals, Inc. |
|
|
|
 |
Adare Pharmaceuticals
Princeton Pike Corporate Center
1200 Lenox Drive, Suite 100
Lawrenceville, NJ 08648
If you would like to unsubscribe from future communications from Adare Pharmaceuticals, please e-mail [email protected]. |
|
|
|
